Gilbert changed his life with Vida
Member Story
Resources
-
The Viewpoint from Vida: what happens after GLP-1s?
Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. But what are the strategic benefits, and what are the risks?
-
7 Reasons Employers and Health Plans Need to Get Ahead of MASH Costs
MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.
-
MASH: The hidden driver of rising costs and cardiometabolic risk
MASH is one of the fastest-growing and most overlooked drivers of metabolic risk and rising healthcare costs.